Forgot your password?
New User?
Remember me
banner banner

You are here:Home » Kits and Assays » Kits-ELISA (Tumor Markers), BioAssay™ » CA19-9 Cancer Antigen, Human (Pancreatic, GI or Ovarian Tumor Antigen, Sialyl Lewis a, Carbohydrate Antigen 19-9) BioAssay™ ELISA Kit

CA19-9 Cancer Antigen, Human (Pancreatic, GI or Ovarian Tumor Antigen, Sialyl Lewis a,
Carbohydrate Antigen 19-9) BioAssay™ ELISA Kit


  For pricing information, USA customers sign in.
  Outside USA? Please contact your distributor for pricing.


A group of mucin type glycoprotein Sialosyl Lewis Antigens (SLA), such as CA19-9 and CA19-5, have come to be recognized as circulating cancer associated antigens for gastrointestinal cancer. CA19-9 represents the most important and basic carbohydrate tumor marker. The immunohistologic distribution of CA19-9 in tissues is consistent with the quantitative determination of higher CA19-9 concentrations in cancer than in normal or inflamed tissues.
Catalog #C0075-03H
Recently reports indicate that the serum CA19-9 level is frequently elevated in the serum of subjects with various gastrointestinal malignancies, such as pancreatic, colorectal, gastric and hepatic carcinomas. Together with CEA, elevated CA19-9 is suggestive of gallbladder neoplasm in the setting of inflammatory gallbladder disease. This tumor-associated antigen may also be elevated in some non-malignant conditions. Research studies demonstrate that serum CA 19-9 values may have utility in monitoring subjects with the above-mentioned diagnosed malignancies.
It has been shown that a persistent elevation in serum CA19-9 value following treatment may be indicative of occult metastatic and/or residual disease. A persistently rising serum CA 19-9 value may be associated with progressive malignant disease and poor therapeutic response. A declining CA 19-9 value may be indicative of a favorable prognosis and good response to treatment.
Sample TypeSerum
Intended UseFor the quantitative determination of the Cancer Antigen CA19-9 concentration in human serum.
Test PrincipleThe CA19-9 ELISA test is based on the principle of a solid phase enzyme-linked immunosorbent assay. The assay system utilizes a monoclonal antibody directed against a distinct antigenic determinant on the intact CA19-9 molecule is used for solid phase immobilization (on the microtiter wells). Another CA 19-9 monoclonal antibody conjugated to horseradish peroxidase (HRP) is in the antibody-enzyme conjugate solution. The test sample is allowed to react sequentially with the two antibodies, resulting in the CA19-9 molecules being sandwiched between the solid phase and enzyme-linked antibodies. After two separate incubation steps at
37°C for 90 minutes, the wells are washed with Wash Buffer to remove unbound labeled antibodies. A solution of TMB Reagent is added and incubated for 20 minutes, resulting in the development of a blue color. The color development is stopped with the addition of Stop Solution changing the color to yellow. The concentration of CA19-9 is directly proportional to the color intensity of the test sample. Absorbance is measured spectrophotometrically at 450nm.
Kit ComponentsMurine monoclonal anti-CA19-9 coated 1x96 well microtiter plate.
Standard, 0U/ml, 1x1ml
Standard, 25U/ml, 1x1ml
Standard, 75U/ml, 1x1ml
Standard, 150U/ml, 1x1ml
Standard, 300U/ml, 1x1ml
Standard, 600U/ml, 1x1ml
CA 19-9 Assay Buffer, 1x13ml
Enzyme Conjugate Concentrate (12X), 1x2ml
CA 19-9 Conjugate Diluent, 1x24ml.
Wash Buffer Concentrate (20X), 1x50ml
TMB Reagent (One-Step), 1x11ml
Stop Solution (1N HCl), 1x11ml
Storage and StabilityStore all components at 4°C. Stable for at least 6 months. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Alternate namesSialyl Lewis (a)

External Links